Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) issued its earnings results on Monday. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.25, FiscalAI reports.
Maplight Therapeutics Trading Down 4.8%
MPLT opened at $6.90 on Tuesday. The company has a 50 day simple moving average of $9.20 and a two-hundred day simple moving average of $19.79. Maplight Therapeutics has a 1-year low of $6.06 and a 1-year high of $40.43.
Insider Activity
In related news, insider James Lillie sold 11,513 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $8.08, for a total value of $93,025.04. Following the completion of the transaction, the insider owned 198,597 shares of the company’s stock, valued at approximately $1,604,663.76. This represents a 5.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Christopher A. Kroeger sold 73,691 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $8.08, for a total transaction of $595,423.28. Following the completion of the transaction, the chief executive officer directly owned 1,195,909 shares of the company’s stock, valued at $9,662,944.72. This represents a 5.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 122,974 shares of company stock worth $990,690. 3.80% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Maplight Therapeutics
Analyst Ratings Changes
A number of brokerages have recently issued reports on MPLT. Craig Hallum reaffirmed a “buy” rating and set a $25.00 price target on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating on shares of Maplight Therapeutics in a report on Monday, July 27th. Morgan Stanley downgraded shares of Maplight Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $34.00 to $21.00 in a research report on Tuesday, July 28th. Guggenheim began coverage on shares of Maplight Therapeutics in a research report on Monday, October 5th. They set a “neutral” rating on the stock. Finally, Raymond James Financial set a $31.00 target price on shares of Maplight Therapeutics in a report on Friday, August 14th. Four equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.50.
Check Out Our Latest Stock Analysis on MPLT
About Maplight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.
Read More
- Five stocks we like better than Maplight Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
